Related Experiment Videos
[Exacerbation of psoriasis during alpha-interferon therapy]
F Hartmann1, P von Wussow, H Deicher
1Zentrum für Innere Medizin und Dermatologie, Medizinische Hochschule Hannover.
Deutsche Medizinische Wochenschrift (1946)
|January 20, 1989
Summary
Recombinant interferon-alpha-2b treatment exacerbated psoriasis in three patients with metastatic melanoma. Lesions resolved after drug discontinuation and corticosteroid therapy, suggesting interferon can induce psoriasis flares at high doses.
Area of Science:
- Oncology
- Dermatology
- Immunology
Background:
- Malignant melanoma is a serious form of skin cancer.
- Interferon-alpha-2b is a biologic therapy used in cancer treatment.
- Psoriasis is a chronic autoimmune skin condition.
Observation:
- Three female patients with metastatic melanoma experienced psoriasis exacerbation.
- The exacerbation occurred during the third week of treatment with recombinant interferon-alpha-2b.
- Dosage was three times 10 million IU weekly.
Findings:
- Psoriatic lesions significantly improved after discontinuing interferon-alpha-2b.
- Systemic corticosteroid administration aided in lesion resolution.
- High-dose interferon-alpha-2b may induce or worsen psoriasis.
Implications:
- Interferon-alpha-2b carries a risk of inducing psoriasis exacerbation in cancer patients.
- Low-dose interferon may have therapeutic potential for psoriasis in non-oncological settings.
- Careful patient monitoring for dermatological side effects is crucial during interferon therapy.